Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo for Maintenance of Weight Loss in Participants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight-Related Comorbidities: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-4)
Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo for Maintenance of Weight Loss in Participants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight-Related Comorbidities: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-4)
This was a study of tirzepatide in participants with obesity or overweight. The main purpose was to learn more about how tirzepatide maintained body weight loss. The study had two phases: a lead-in phase in which all participants took tirzepatide and a treatment phase in which participants either continued tirzepatide or switched to placebo. The study lasted about 2 years (25 visits).
Inclusion Criteria:
Exclusion Criteria:
Hyattsville, Maryland 20782, United States
Troy, Michigan 48098, United States
Winston-Salem, North Carolina 27157, United States
North Richland Hills, Texas 76180, United States
CABA, Buenos Aires C1060ABN, Argentina
CABA, Buenos Aires C1120AAC, Argentina
Ciudad Autónoma de Buenos Aire, Buenos Aires C1023AAB, Argentina
Ciudad Autonoma de Buenos Aire, Ciudad Autónoma de Buenos Aire C1425AGC, Argentina
São José dos Campos, São Paulo 12243-280, Brazil